Search - tctmd.com

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

BMS vs. MIDCAB at 10 Years: Results Similar for LAD Disease, TVR Higher with PCI

Jason Kahn

January 24, 2013

Advertisement

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Women vs. Men in BARI 2D: Equal Survival but Worse Quality of Life

Tirofiban on Top of Endovascular Therapy for Acute Stroke Tied to Fatal Hemorrhage

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Transcatheter Mitral Valve-in-Valve Procedure Benefits Inoperable Patients

Medtronic Approved to Update Resolute Integrity Stent’s ‘CE’ Mark Labeling on Dual Antiplatelet Therapy

Un Documento de la ESC Orienta sobre el Uso Doble de IBP y Antitrombóticos

ESC Position Paper Offers Guidance on Dual PPI and Antithrombotic Use

AIDA STEMI Substudy Confirms No Advantage for Intracoronary Abciximab

La Atorvastatina Potencia la Eficacia del Clopidogrel en Pacintes con Alta Reactividad Plaquetaria

Atorvastatin Boosts Clopidogrel Efficacy in Patients with High Platelet Reactivity

ACS Patients Benefit After Switching from Prasugrel to Clopidogrel but at a Cost

A-fib—Whether New or Preexisting—Raises Mortality in Patients Undergoing TAVR

ISAR-DESIRE 3 Published: Paclitaxel-Eluting Balloons Match PES for DES Restenosis

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

BMS vs. MIDCAB at 10 Years: Results Similar for LAD Disease, TVR Higher with PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content